These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 8968342

  • 1. In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep.
    Widness JA, Veng-Pedersen P, Schmidt RL, Lowe LS, Kisthard JA, Peters C.
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1205-10. PubMed ID: 8968342
    [Abstract] [Full Text] [Related]

  • 2. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway.
    Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA.
    J Pharmacol Exp Ther; 2001 Aug; 298(2):820-4. PubMed ID: 11454947
    [Abstract] [Full Text] [Related]

  • 3. Comparative pharmacokinetics and distribution of human urinary erythropoietin and recombinant human erythropoietin in rats.
    Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A.
    Arzneimittelforschung; 1991 Sep; 41(9):1004-7. PubMed ID: 1796912
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats.
    Yoon WH, Park SJ, Kim IC, Lee MG.
    Res Commun Mol Pathol Pharmacol; 1997 May; 96(2):227-40. PubMed ID: 9226757
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics.
    Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.
    Drug Metab Dispos; 1997 Sep; 25(9):1039-44. PubMed ID: 9311618
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin.
    Misaizu T, Matsuki S, Strickland TW, Takeuchi M, Kobata A, Takasaki S.
    Blood; 1995 Dec 01; 86(11):4097-104. PubMed ID: 7492766
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses.
    Souillard A, Audran M, Bressolle F, Jaussaud P, Gareau R.
    Biopharm Drug Dispos; 1996 Dec 01; 17(9):805-15. PubMed ID: 8968532
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats.
    Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.
    J Pharmacol Exp Ther; 1997 Nov 01; 283(2):520-7. PubMed ID: 9353365
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.
    Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA.
    Biopharm Drug Dispos; 2004 May 01; 25(4):149-56. PubMed ID: 15108217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.